EP0901536B1 - Schallschutzeinrichtung für gleise - Google Patents

Schallschutzeinrichtung für gleise Download PDF

Info

Publication number
EP0901536B1
EP0901536B1 EP97922748A EP97922748A EP0901536B1 EP 0901536 B1 EP0901536 B1 EP 0901536B1 EP 97922748 A EP97922748 A EP 97922748A EP 97922748 A EP97922748 A EP 97922748A EP 0901536 B1 EP0901536 B1 EP 0901536B1
Authority
EP
European Patent Office
Prior art keywords
slab
sound
proofing device
carrying
portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97922748A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0901536A1 (de
Inventor
Bernhard Neumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gmundner Fertigteile GmbH and Co KG
Original Assignee
Gmundner Fertigteile GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT93496A external-priority patent/AT403809B/de
Priority claimed from AT0101596A external-priority patent/AT405426B/de
Application filed by Gmundner Fertigteile GmbH and Co KG filed Critical Gmundner Fertigteile GmbH and Co KG
Priority to SI9730491T priority Critical patent/SI0901536T1/xx
Publication of EP0901536A1 publication Critical patent/EP0901536A1/de
Application granted granted Critical
Publication of EP0901536B1 publication Critical patent/EP0901536B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01B—PERMANENT WAY; PERMANENT-WAY TOOLS; MACHINES FOR MAKING RAILWAYS OF ALL KINDS
    • E01B19/00—Protection of permanent way against development of dust or against the effect of wind, sun, frost, or corrosion; Means to reduce development of noise
    • E01B19/003—Means for reducing the development or propagation of noise

Definitions

  • the invention relates to a soundproofing device for tracks, on the rails the sound-absorbing plates mounted on the track, which have elastic profiles the rails are supported, the plates arranged between the rails Bridge the space between the rails in a self-supporting manner.
  • the invention further relates on sound absorbing panels for such a soundproofing device.
  • the plates arranged between the rails of the track consist of three layers or layers that extend over elastic profiles on the rail foot, Support the web and the underside of the head.
  • the upper layer consists of steel wire mesh, the edge of which is glued, welded or vulcanized into the profile.
  • the middle layer is designed as a sound absorption layer and consists of glass wool or rock wool. This sound absorption layer lies on the lower layer, which is designed as a perforated wall or grate and is supported in a recess in the profile in the region of the rail foot.
  • the plates are also arranged on the outside of the rail and angled upward at the ends in order to form a lateral soundproofing wall.
  • Such mineral wool panels have sufficient sound absorption at high frequencies, but have inadequate sound insulation at low frequencies.
  • Another disadvantage of this construction is that the walkable perforated wall made of steel wire mesh can become detached from its anchoring in the profiles at higher and repeated loads, so that the sound absorption layer underneath can be damaged.
  • the dust penetrating through the perforated wall can be deposited on the top of the sound absorption layer and thus the sound damping effect can deteriorate progressively.
  • a soundproofing device for tracks is known in which panels made of wood fiber concrete are arranged between the rails of the track, which rest on the sleepers of the track and laterally more elastic with an intermediate layer Lay strips on the rails. There is no unsupported storage of these plates.
  • the invention has for its object to provide a soundproofing device for tracks sound-absorbing panels to create a good sound absorption or damping over the entire frequency range essential for the sound level of rail traffic has, with a permanent mechanical Strength of the device should be guaranteed.
  • the soundproofing device initially mentioned type according to the invention solved in that the Plates consist of particles made of porous lightweight material, which are connected at certain points with a binder, and that the Slabs have embedded reinforcement and are uncovered are.
  • the above can Objectives are met well.
  • the particular of the wheels of a rail vehicle and from the rails Airborne sound is emitted from the surface of the panels
  • Pores of the particles are absorbed and can also fine spaces between the particles, leaving the structure through spaces or channels between the particles penetrate deeper into the plate to gradually complete there to be subdued. Due to the reinforcement of the slabs too ensures their accessibility.
  • the plates is advantageously provided that the top of the panels is textured, being even better Results can be achieved if the structuring is irregular is.
  • the top of the plates is preferably parallel to the rails extending ribs, whereby a structurally simple to manufacture results.
  • the ribs have a trapezoidal shape Have a cross-section, as this means that the angle falls Sound waves can be better absorbed.
  • the wall of the cavity resonators and their sound openings with a sound absorbing structure are provided, and / or if the wall of the cavity resonators and their tubular sound openings with a sound-absorbing layer are provided.
  • the cavities forming the cavities after are designed to be open at the bottom and with a lower plate are covered.
  • the cavity resonators forming cavities open downwards are trained and together with the track bed Form resonance cavity.
  • the damped resonance frequency of the cavity resonators within a frequency range from 150 to 1000 Hz, preferably is between 500 and 1000 Hz.
  • a special embodiment is also within the scope of the invention provided in which the installation and removal the one to be provided between the two rails of a track Plates can be done in a very simple way.
  • This embodiment of the soundproofing device is thereby characterized in that the one between the two rails
  • the track lying space is bridged with partial plates arranged in pairs is, each with at least one support rib in the Latch chambers of the rails engage, the partial plates each pair of plates on their mutually facing edges are supported on each other and in this case with each partial plate meandering along the edge facing the other partial plate alternating successive support sections and support sections are provided, wherein the support sections through by the Outgoing plate top and up to the other partial plate facing depressions are formed and under the supporting sections starting from the underside of the plate Indentations above are formed, which are complementary are formed to the depressions of the support sections, and the Supporting sections of a partial plate on the support sections of the other sub-plate and the support sections of the other sub-plate rest on the support sections of a partial plate.
  • Plate pairs can be used when the partial plates are unfolded simply put together, after which the partial panels are no problem leveling the pair of plates between the rails can be inserted, and it will also be the sub-panels Loads not pushed apart.
  • a preferred type of the latter embodiment which is characterized in that on those surfaces which the partial plates of a plate pair lie against each other, Projections and depressions shaped complementary to the projections, in which the projections snap into place for mutual Locking of the partial plates are provided, has the advantage that the cohesion of the partial plates of a plate pair also is secured over a very long period of time even when unfavorable Vibrations affect the sub-panels.
  • Such a crowning can be on one Partial plate by one, of which the other partial plate of the Plate pair facing edge outgoing surface section, the extending from the underside of the plate, and a subsequent surface section, which is the bottom approaching the plate are formed. If you want one such formation of the sub-plates additionally a latching it is advantageous if you train them to that down at the end edges of the support sections pointing projections and on the wings of the support sections complementary depressions are provided for these projections.
  • the domed wings are shaped according to a toothing, which up to for leveling the position of the partial plates of the respective plate pair a sliding movement or rolling movement of each other facing wings and supporting surfaces on each other and in the leveled position of these partial plates against one Movement of these partial plates to each other blocks.
  • Partial plates favorable geometry, if one provides that the partial plates on the mutually facing edges from the underside of the plate starting from the top to be rounded, whereby the radius of curvature is equal to or less than the distance between these edges and the rail side edges of the Is partial panels. It is also a simple assembly the partial plates of a plate pair advantageous, if one provides that the two partial plates of a pair of plates on the underside of the plate approximately along a straight line apart. However, if you want the highest possible load capacity of the plate pair, it is favorable if one provides that the two partial plates of a plate pair on the The underside of the plate should be meandering.
  • the reinforcement provided in the sub-slabs changes extends over the plate surface and into the support sections and engages in the support sections and in the support ribs. It is also cheap if you provide that between the on the support sections provided wings and on the support sections provided support surfaces an elastic and / or shock-absorbing insert or coating is provided.
  • a sound absorbing plate according to the invention is thereby characterized in that the plate is made of porous particles
  • Lightweight material is made, which is connected at certain points with a binder are that the plate on opposite edges with support ribs for engaging in the link chambers of rails, that the plate has an embedded surface reinforcement, and that in the plate cavity resonators with one Large area of the plate directed tubular sound openings, whose cross section is significantly smaller than the cross section of the cavity resonators, are formed, which large area to form the top is provided when installing the plate in the track.
  • Hiebei is it is advantageous if those forming the cavity resonators Cavities to the large area that the tubular Side of the plate facing away from the sound openings, expanding are openly trained.
  • Embodiments of a plate designed according to the invention which for the aforementioned Training with partial plates to be assembled into a pair of plates are provided, are characterized in that the Plate consists of particles made of porous lightweight material, which with a binder are put together so that the plate is an embedded Reinforcement has that the plate on one edge side with a support rib for engaging in the tab chambers of Rails is provided and on the opposite of this support rib Edge side in meandering succession of supporting sections and has support portions, the support portions by starting from the top of the plate and up to the edge reaching depressions are formed and under the support sections starting from the underside of the plate, facing upwards Depressions are formed, which are complementary to the Depressions of the support sections are shaped.
  • the plate cavity resonators with a large area of the plate directed tubular sound openings are formed, which large area to form the Top is provided when installing the plate in the track. It is further advantageous if the provided in the plate Reinforcement extends over the entire slab area and in the support sections and in the support sections and in the Rib is enough. If desired, the plates or partial plates also with a preferably running along the edge made of metal or fiber-reinforced plastic, Frame.
  • the generally rectangular Plates 3 have the rails 2 along both of them extending edges projecting support ribs 4, which with the interposition of elastic profiles 5, e.g. made of rubber or elastomer, on the rail base 6, on the rail web 7 and on the Support the underside of the rail head 8 of the rails 2.
  • a lightweight material used for example plastic granules, granular or spherical and fired alumina particles, granular slag particles, or similar burned natural or artificial manufactured materials
  • these particles with a suitable Plastic binders or cement are connected at certain points, so that small gaps or channels 10 remain, one Air shutter pipe and a drain of penetrating rain or Allow melt water.
  • the one on the plates 3 impinging airborne sound is on the surface of the plates 3 absorbed by the pores of the particles 9 and can via the gaps or channels remaining between the particles 9 10 penetrate deeper into the plate 3 to gradually be absorbed there to become.
  • the surface of the plates 3 by structuring be enlarged.
  • the top 12 of the Plates 3 with parallel to the rails 2 and in Spaced ribs 13 may be provided, which, as shown in Figure 3, a trapezoidal cross-section and have a height a above the rail head 8, which is a permissible Value of e.g. Not exceed 5 cm.
  • the structuring can also be irregular, e.g. the distance of the Ribs 13 increases or decreases relative to each other.
  • the Top 12 can also, for example, truncated cones, truncated pyramids, Cylinders, cuboids, etc. can be provided either in the same or at different distances from each other are.
  • the tubular sound openings 15 are provided on the top 12 of the plates 3.
  • the cavity resonators 14 forming cavities frusto-conical and down formed open, the openings thus formed through one, e.g. glued to the plate 3, sub-plate 16 covered are to form the cavity resonator 14.
  • the cavities forming the cavity resonators left open at the bottom so that it can be the only shown schematically with a dash-dotted line Track bed 17 (e.g.
  • the cavities forming cavities 14 can also be of the Conical shape different, e.g. spherical, cylindrical, pyramid-shaped, etc. to be different To achieve frequency behavior in sound absorption.
  • the volumes of the cavity resonators 14 and Dimensions of the tubular sound openings can be varied in order the desired frequency response or frequency absorption spectrum to achieve.
  • the tubular sound openings 15 open, as shown in Figure 2, perpendicular to the top 12 of the plate 3. In a variation of this arrangement, the tubular sound openings 15 also open at an angle to the top 12 of the plates 3, to better absorb oblique sound waves.
  • the manufacture of the plates 3 with the cavity resonators 14 can be done in a rectangular shape, in the positive shapes the cavity resonators with attached pipe pieces for the sound openings are used, whereupon the shape with the Particle 9 and a binder filled and after curing of the binder is removed from the mold.
  • too prefabricated cavity resonators with attached pipe sections can be used as a sound opening in the form, either consist of a suitable sound absorbing material or provided with a layer of sound-absorbing material on the inside are.
  • the rails 2 can also on the outside of the rail the rails 2 sound absorbing plates with cavity resonators be provided.
  • the one on the right rail 2 Plate 18 shown with a dash-dotted line is on one End, similar to the plate 3 lying between rails 2 the rail 2 via an elastic profile 5 and at the other end supported by an elastic strip 19 and by means of a Fastening element, in particular a screw 20, fixed.
  • the one on the left rail 2, also with dash-dotted lines Plate 21 shown in line is the same as that Plate 18 supported and fixed, but has one on the outside end area bent at the top to create a soundproof wall form.
  • the two plates 18, 21 also have reinforcement (not shown) and, if necessary, structuring in the form of ribs (not shown). If desired, you can also use a plate that runs along the edge Frame.
  • a soundproofing device designed according to the invention the space between the two rails 2 of a track 1 22 with paired sound-absorbing partial plates 3a, 3b filled or bridged.
  • These partial plates 3a, 3b have Support ribs 4, which in the tab chambers 23 of the rails 2nd intervene, and there are between the support ribs 4 and Rails 2 elastic profiles 5 with an approximately C-shaped cross section inserted.
  • the partial plates 3a, 3b are included their support ribs 4 on the rail base 6 and laterally against the Rail web 7 supported and upwards by engagement under held the rail head 8.
  • Bridge the partial plates 3a, 3b the distance 24 between the rails 2 is self-supporting.
  • each of the partial plates 3a, 3b is provided with a plurality of supporting ribs 4, which are spaced from each other by the for the Rails 2 provided fasteners 25 accessible to let. But you can also choose a different plate size and panel mounting arrangement on each panel as well provide only one support rib 4.
  • each partial plate 3a and 3b along the the other partial plate 3b or 3a facing edge 15 or 16 meandering alternating successive support sections 28th and support sections 29 are provided, the support sections 28 through depressions 30 starting from the top 12 of the plate are formed, which face up to that of the other partial plate Reach the edge; under the support sections 29 are of the Plate underside 31 outgoing, upward, depressions 32 formed, and there are the support portions of the Sub-plate 3a on the support portions of sub-plate 3b and Supporting sections of the partial plate 3b on the support sections of the Partial plate 3a on; the depressions 30 are to the depressions 32 designed complementary, so that on the support sections 29 formed by the depressions 32 support surfaces 34 in substantially full on the through the depressions 30 on the Support sections 28 formed wings 33 rest.
  • the wings 33 provided in the support sections 28 have a cambered shape, and there is such a cambered Shape also in the support surfaces provided on the support sections 29 34 before, and it is due to this cambered form of the above Surfaces create a form cohesion of the partial plates 3a, 3b, which in the leveled position of the partial plates 3a, 3b a mutual movement of these partial plates in the direction the plate level (arrows 36) inhibits. Furthermore, are on the support surfaces 34 projections 37 and 33 wells on the wings 38, which are complementary to the projections 37, provided; in the leveled position of the partial plates, the Projections 37 into the recesses 38 so that there is a mutual locking of the partial plates 3a, 3b results.
  • an elastic and / or shock-braking effect Inlay or coating can be provided.
  • the wings 33 provided on the support sections extend from the edge 26 or 27 of the relevant sub-plate 3a or 3b starting, first steep away from the underside 31 of the plate rising and then flattening, what kind of joining the partial plates to the plate pairs is advantageous. Geometric seen it is favorable if such a domed shape Wings are shaped according to a toothing, which up to the leveled position of the partial plates 3a, 3b of the respective Plate pair a sliding movement or rolling movement of the wings and support surfaces facing each other enables, and in the leveled position (Fig. 5 to 7) locks these partial plates against movement to one another. This surface shape corresponding geometrically to a toothing can extend to the top of the plate 12.
  • the projections 37 can, as shown in FIGS. 5 to 8, provided on the end edges 39 of the support sections 29 be what brings advantages when joining the sub-panels may, but it is also possible to such projections 37 on others Position, e.g. slightly moved away from the edge of the support surfaces.
  • Both in the embodiment shown in Figures 5 to 7 as well as in the variant shown in Fig.10 are the two partial plates 3a, 3b of a plate pair on the Underside of plate 31 interlocking, so that the mutually facing edges of the partial plates 3a, 3b run along the underside of the plate following a meandering line 43. This results in a very close bond of the partial plates 3a, 3b forming a pair of plates.
  • FIGS. 11 to 16 are the partial plates 3a, 3b on the mutually facing edges 26, 27 starting from the underside of the plate 31 rounded upwards shaped, the radius of curvature of this rounding equal to or less than the distance 41 between the Edges 26, 27 and the rail-side edges 42 of the partial plates 3a, 3b. This measure is also possible for you uninhibited process of inserting the partial panels advantageous.
  • the reinforcement 11 provided in the sub-slabs over the whole surface extension of the partial plates 3a, 3b is sufficient and here, as indicated by the broken line in FIG. 8, both in the support sections 28 and in the support sections 29 as well as in the support ribs 4 engages.

Landscapes

  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Building Environments (AREA)
  • Soundproofing, Sound Blocking, And Sound Damping (AREA)
  • Railway Tracks (AREA)
  • Devices Affording Protection Of Roads Or Walls For Sound Insulation (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Magnetic Heads (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Bridges Or Land Bridges (AREA)
  • Noise Elimination (AREA)
  • Holo Graphy (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
EP97922748A 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise Expired - Lifetime EP0901536B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9730491T SI0901536T1 (en) 1996-05-29 1997-05-23 Track soundproofing arrangement

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AT93496 1996-05-29
AT93496A AT403809B (de) 1996-05-29 1996-05-29 Schallschutzeinrichtung für gleise
AT934/96 1996-06-11
AT0101596A AT405426B (de) 1996-06-11 1996-06-11 Schienengleiche eindeckung für gleise
AT101596 1996-06-11
AT1015/96 1996-06-11
PCT/AT1997/000109 WO1997045592A1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise

Publications (2)

Publication Number Publication Date
EP0901536A1 EP0901536A1 (de) 1999-03-17
EP0901536B1 true EP0901536B1 (de) 2002-12-11

Family

ID=25594370

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97922748A Expired - Lifetime EP0901536B1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise

Country Status (14)

Country Link
US (1) US6253872B1 (cg-RX-API-DMAC7.html)
EP (1) EP0901536B1 (cg-RX-API-DMAC7.html)
JP (1) JP3822641B2 (cg-RX-API-DMAC7.html)
CN (1) CN100424268C (cg-RX-API-DMAC7.html)
AT (1) ATE229595T1 (cg-RX-API-DMAC7.html)
AU (1) AU738889B2 (cg-RX-API-DMAC7.html)
CA (1) CA2255946C (cg-RX-API-DMAC7.html)
DE (1) DE59708955D1 (cg-RX-API-DMAC7.html)
DK (1) DK0901536T3 (cg-RX-API-DMAC7.html)
ES (1) ES2186891T3 (cg-RX-API-DMAC7.html)
HU (1) HU221872B1 (cg-RX-API-DMAC7.html)
NO (1) NO316078B1 (cg-RX-API-DMAC7.html)
TW (1) TW345603B (cg-RX-API-DMAC7.html)
WO (1) WO1997045592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (307)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19812481C2 (de) * 1998-03-21 2002-08-22 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
DE29905550U1 (de) * 1999-03-26 2000-08-24 DVG Deutsche Verpackungsmittel GmbH, 90552 Röthenbach Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
DE10111919A1 (de) * 2001-03-13 2002-09-19 Boegl Max Bauunternehmung Gmbh Fahrwegträger
HU224236B1 (hu) * 2001-12-14 2005-06-28 Attila Szebeni Vasúti acélhidaknál alkalmazható, egymáshoz csatlakoztatott elemekbõl álló, zaj- és rezgéscsökkentett mûanyag járólemezrendszer
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
AU2003249742A1 (en) 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
AT6414U1 (de) * 2002-07-17 2003-10-27 Gmundner Fertigteile Gmbh Gleisabdeckung
GB2399123B (en) * 2003-03-05 2006-03-01 Corus Uk Ltd Rail damper
US20040248877A1 (en) * 2003-04-30 2004-12-09 Sandeep Gupta Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
BRPI0410348A (pt) * 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US7546900B2 (en) * 2004-02-12 2009-06-16 Evonik Cyro Llc Panel assembly for traffic noise barrier wall
US8616331B2 (en) 2004-02-12 2013-12-31 Eric C. Humphries Panel assembly for traffic noise barrier wall
US20100126797A1 (en) * 2004-02-12 2010-05-27 Humphries Eric C Panel Assembly For Traffic Noise Barrier Wall
TWI347390B (en) * 2004-03-05 2011-08-21 Gmundner Fertigteile Gmbh Noise-reducing track cover
US20050261365A1 (en) 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
EP1802303B1 (en) 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20070131480A1 (en) * 2004-12-06 2007-06-14 Corbin Maxwell H Jr Sound arresting barrier
US7464791B2 (en) * 2005-01-27 2008-12-16 Pretty Products, Llc Acoustic mats and methods for making the same
US20060230699A1 (en) * 2005-03-22 2006-10-19 Keene James R Sound control flooring systems and methods therefor
CN101189249B (zh) 2005-04-01 2013-04-17 加利福尼亚大学董事会 膦酰基-戊-2-烯-1-基核苷和类似物
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US8063221B2 (en) * 2006-03-13 2011-11-22 Kyorin Pharmaceutical Co., Ltd. Aminoquinolones as GSK-3 inhibitors
WO2007126841A2 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
WO2007143781A1 (en) * 2006-06-13 2007-12-21 Newstyle Nominees Pty Ltd Rail track crossing
KR101374983B1 (ko) 2006-08-28 2014-03-17 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
DK2066662T3 (da) 2006-09-21 2013-01-07 Kyorin Seiyaku Kk Serinhydrolaseinhibitorer
DE602007013440D1 (de) 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
JP5013590B2 (ja) * 2006-11-14 2012-08-29 エンデバーハウス株式会社 伸縮性に優れた線路用吸音材
AU2007333667A1 (en) 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of CCR5 inhibitors
AU2007338689A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of C3a receptor and methods of use thereof
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
DK2144604T3 (da) 2007-02-28 2011-10-17 Conatus Pharmaceuticals Inc Fremgangsmåder til behandling af kronisk viral hepatitis C under anvendelse af RO 113-0830
EP3269706A1 (en) 2007-03-15 2018-01-17 Auspex Pharmaceuticals, Inc. Deuterated o-desmethylvenlafaxine with serotoninergic and/or norepinephrinergic activity
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
JP2010533205A (ja) * 2007-07-12 2010-10-21 トラガラ ファーマシューティカルズ，インク． 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物
CA2699151A1 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
JP5373799B2 (ja) 2007-09-12 2013-12-18 杏林製薬株式会社 Ｇｓｋ−３阻害剤としてのスピロ環式アミノキノロン
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CN101849068B (zh) * 2007-11-07 2013-01-02 何伟麟 可调谐震动吸收装置
CN101917845A (zh) 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
NZ587907A (en) 2008-03-17 2012-09-28 Ambit Biosciences Corp Quinazoline derivatives as RAF kinase modulators and methods of use thereof
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US8048204B2 (en) 2008-09-23 2011-11-01 Rwdi Air Inc. Wall assembly
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
AU2010217929B2 (en) 2009-02-27 2016-07-14 Ambit Biosciences Corporation JAK kinase modulating quinazoline derivatives and methods of use thereof
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
MX2011009414A (es) * 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
US8146310B2 (en) * 2009-03-11 2012-04-03 Keene Building Products Co., Inc. Noise control flooring system
WO2010105016A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
MX2011010105A (es) 2009-03-27 2012-01-12 Pathway Therapeutics Inc Sulfonamidas de pirimidinilo y 1,3,5-triazinilo benzimidazol y su uso en terapia de cancer.
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
PE20120811A1 (es) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Antagonistas ccr3 arilsulfonamida
AR078120A1 (es) 2009-04-22 2011-10-19 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas
CA2758968C (en) 2009-04-22 2018-05-29 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide ccr3 antagonists
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
AR080945A1 (es) 2009-07-07 2012-05-23 Pathway Therapeutics Inc Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer
WO2011005841A1 (en) 2009-07-08 2011-01-13 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
NL2003697C2 (nl) 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
EP2499282B1 (en) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US8528286B2 (en) * 2009-11-10 2013-09-10 Keene Building Products Co., Inc. Sound control mat
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
NZ600608A (en) 2009-12-18 2015-01-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
HUE025699T2 (en) 2010-03-02 2016-04-28 Axikin Pharmaceuticals Inc Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US8741894B2 (en) 2010-03-17 2014-06-03 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
CN103038216A (zh) 2010-06-01 2013-04-10 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
WO2011153199A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
WO2011156321A1 (en) 2010-06-07 2011-12-15 Novomedix, Llc Furanyl compounds and the use thereof
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
US8703943B2 (en) 2010-09-01 2014-04-22 Ambit Biosciences Corporation Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
ES2619850T3 (es) 2010-09-01 2017-06-27 Ambit Biosciences Corporation Sales de hidrobromuro de una pirazolilaminoquinazolina
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030914A1 (en) 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
US20120125711A1 (en) * 2010-11-24 2012-05-24 Stahr Richard E Sound absorbing panel and system
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2723735A4 (en) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc NOVEL ANALOGUES OF FLUORO-ERGOLINE
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
CN104066730B (zh) 2011-10-14 2017-03-08 埃姆比特生物科学公司 杂环化合物及其作为iii型受体酪氨酸激酶调节剂的用途
US8592445B2 (en) 2011-12-19 2013-11-26 Map Pharmaceuticals, Inc. Iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
MX2014011115A (es) 2012-03-16 2015-03-13 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol cinasa.
MX377635B (es) 2012-05-02 2025-03-11 Boehringer Ingelheim Int Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
DK2877493T3 (en) 2012-07-25 2018-06-14 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
BR112015004959A2 (pt) 2012-09-07 2017-07-04 Axikin Pharmaceuticals Inc composto isotopicamente enriquecido, composição farmacêutica, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença, distúrbio ou condição mediada por ccr3, relacionada a eosinófilos, relacionada a basófilos, relacionada a mastócitos ou relacionada a mastócitos em um sujeito, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença inflamatória em um sujeito e método para modular a atividade de ccr3.
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
EP2916830A2 (en) 2012-11-08 2015-09-16 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
EP3447046A1 (en) 2012-11-30 2019-02-27 Novomedix, LLC Substituted biaryl sulfonamides and the use thereof
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2014100354A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
DK3019662T3 (da) * 2013-07-07 2020-12-07 4Silence B V Diffraktionsanordning til diffraktion af lyd
SG11201601341QA (en) 2013-08-30 2016-03-30 Ambit Biosciences Corp Biaryl acetamide compounds and methods of use thereof
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN106661027B (zh) 2014-03-20 2019-12-24 卡佩拉医疗公司 苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
AU2015231202B9 (en) 2014-03-20 2019-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
RU2016148364A (ru) 2014-05-12 2018-06-13 Конатус Фармасьютикалз, Инк. Лечение осложнений хронического заболевания печени
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
SG10201902137PA (en) 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
AU2015369690B2 (en) 2014-12-23 2019-01-17 SMA Therapeutics Inc. 3,5-diaminopyrazole kinase inhibitors
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
HK1247203A1 (zh) 2015-01-28 2018-09-21 上海复旦张江生物医药股份有限公司 取代的咪唑并[1，2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
HRP20201031T1 (hr) 2015-05-29 2020-10-16 Agenus Inc. Anti-ctla-4 protutijela i postupci njihove upotrebe
JP6919099B2 (ja) 2015-06-23 2021-08-18 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 神経学的疾患または障害を処置するためのｖｍａｔ２阻害剤
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
HRP20240304T1 (hr) 2015-10-30 2024-05-10 Neurocrine Biosciences, Inc. Soli valbenazin dihidroklorida i njihovi polimorfi
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
CN121181546A (zh) 2015-12-02 2025-12-23 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
MX385964B (es) 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
JP2019513151A (ja) 2016-03-08 2019-05-23 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． カンプトテシン誘導体及びその使用
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US20190160052A1 (en) 2016-05-13 2019-05-30 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
CA3024508A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
DE102016111064A1 (de) * 2016-06-16 2017-12-21 Vossloh-Werke Gmbh Elastisches Element für einen Befestigungspunkt für eine Schiene für Schienenfahrzeuge und Befestigungspunkt
CN106087611B (zh) * 2016-06-20 2019-07-12 勾厚渝 轨道交通构件
JP2019525772A (ja) 2016-07-08 2019-09-12 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
KR20190058550A (ko) 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
EP4400171A3 (en) 2016-12-02 2024-09-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
KR20190108146A (ko) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2018220515B2 (en) 2017-02-17 2022-06-30 DayLife LLC Universal antivenom
CN116730921A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
MX2019011624A (es) 2017-03-27 2019-12-05 Celgene Corp Metodos y composiciones para la reduccion de la inmunogenicidad.
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
MA50958A (fr) 2017-04-21 2020-10-14 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
US11155613B2 (en) 2017-06-27 2021-10-26 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating fibrosis
WO2019003162A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, MEMBER A5, FOR THE TREATMENT OF GLAUCOMA
AU2018291082B2 (en) 2017-06-27 2025-05-29 Neuracle Science Co., Ltd. Anti-FAM19A5 antibodies and uses thereof
AU2018291081B2 (en) 2017-06-27 2025-02-20 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating cancers
EP4265257A1 (en) 2017-09-01 2023-10-25 East Carolina University Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
CN111263820B (zh) 2017-10-02 2024-07-02 纽洛可科学有限公司 抗序列相似家族19成员a5抗体用于治疗和诊断情绪障碍的用途
CA3076920A1 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California Immunomodulatory oligosaccharides
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
TWI823890B (zh) 2018-01-10 2023-12-01 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
CN119607195A (zh) 2018-04-24 2025-03-14 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
US11970532B2 (en) 2018-05-10 2024-04-30 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CN108533609B (zh) * 2018-06-27 2020-03-10 贵州筑信达创科技有限公司 导轨及滑动件的组合结构
CN108836091B (zh) * 2018-06-27 2020-12-04 贵州筑信达创科技有限公司 导轨
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
EP3824287A1 (en) 2018-07-20 2021-05-26 Pierre Fabre Médicament Receptor for vista
JOP20200336A1 (ar) 2018-08-15 2020-12-22 Neurocrine Biosciences Inc طرق إعطاء مثبطات vmat2 معينة
MA53238A (fr) 2018-08-17 2022-04-13 Eidos Therapeutics Inc Formules d'ag10
CN112969503A (zh) 2018-10-03 2021-06-15 斯塔滕生物技术有限公司 对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
WO2020079595A1 (en) 2018-10-16 2020-04-23 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies
EP3880231A1 (en) 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
US12247070B2 (en) 2018-12-27 2025-03-11 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating atherosclerosis
CA3117619A1 (en) 2019-01-02 2020-07-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
EP3921038A1 (en) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
CN119735688A (zh) 2019-02-26 2025-04-01 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
EP3935042B1 (en) 2019-03-07 2024-08-28 NOBO Medicine Inc. Caspase inhibitors and methods of use thereof
ES3036313T3 (en) 2019-05-20 2025-09-17 Nirvana Sciences Inc Narrow emission dyes, compositions comprising same, and methods for making and using same
JP7754724B2 (ja) 2019-05-20 2025-10-15 ニルバナ サイエンシーズ インク． 発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Ｉｌ－１７ａモジュレーターおよびその使用
KR102337657B1 (ko) * 2019-11-06 2021-12-09 한국철도기술연구원 철도진동저감용 조립식 블록 및 이를 이용한 블록 구조물
JP2023512456A (ja) 2020-01-13 2023-03-27 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
CN113136745B (zh) * 2020-01-17 2024-10-25 洛阳双瑞橡塑科技有限公司 一种轨道道床吸音减振装置
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
JP2023512657A (ja) 2020-02-05 2023-03-28 ワシントン・ユニバーシティ Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
WO2021242891A1 (en) * 2020-05-27 2021-12-02 Mute Wall Systems, Inc. Sound dampening barrier wall
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (en) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP2023532312A (ja) 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
CN116615236A (zh) 2020-11-05 2023-08-18 新免疫技术有限公司 用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法
CN112712784B (zh) * 2020-11-30 2024-12-31 南京华秦光声科技有限责任公司 一种低频宽带平板吸声结构
WO2022132603A1 (en) 2020-12-14 2022-06-23 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
WO2022164997A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
CN117642396A (zh) 2021-03-10 2024-03-01 戴斯分子Sv有限公司 αVβ6和αVβ1整联蛋白抑制剂及其用途
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4347826A1 (en) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
AU2022292649A1 (en) 2021-06-16 2024-01-04 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4410311A4 (en) 2021-09-29 2025-12-17 Nbios Inc FUSION PROTEIN WITH WINDED COIL CORE
WO2023069770A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
EP4433040A4 (en) 2022-01-03 2025-11-12 Lilac Therapeutics Inc ACYCLIC THIOL PRODRUGS
KR20230125129A (ko) 2022-02-17 2023-08-29 주식회사 노벨티노빌리티 항체-약물 접합체
CN118922189A (zh) 2022-03-02 2024-11-08 线粒体能量有限公司 衍生自烟酸和核糖的新型前药
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US12187699B2 (en) 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
CA3257018A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. METHOD FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
IL316794A (en) 2022-05-10 2025-01-01 Biotheryx Inc CDK protease inhibitors, pharmaceuticals and therapeutic applications
CA3253951A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. NR4A3 Targeted Polynucleotides and Their Uses
CA3267079A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DOUBLE CK1α/GSPT1 DEGRADATION COMPOUNDS
EP4593826A1 (en) 2022-09-30 2025-08-06 Boulder Bioscience LLC Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
CA3268194A1 (en) 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. HETEROMERIC AGONIST ANTIBODIES DIRECTED AGAINST IL-18 RECEPTOR
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
EP4608839A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
EP4626865A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
EP4626864A1 (en) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
KR102870410B1 (ko) * 2022-12-09 2025-10-16 한국전자기술연구원 방음재 및 소음 제어 시스템
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
CN121057752A (zh) 2023-04-07 2025-12-02 达科纳治疗有限公司 铰链经修饰的双特异性抗体
WO2024211796A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
US20240368596A1 (en) 2023-05-05 2024-11-07 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
WO2024233642A1 (en) 2023-05-09 2024-11-14 Progentos Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2024243048A1 (en) 2023-05-19 2024-11-28 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
TW202515919A (zh) 2023-09-01 2025-04-16 比利時商艾托斯比利時公司 抗ｔｒｅｍ２抗體及使用方法
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202530223A (zh) 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
US20250179197A1 (en) 2023-10-23 2025-06-05 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991848A (en) * 1974-08-16 1976-11-16 Frigitemp Acoustical board
US4142468A (en) * 1976-04-20 1979-03-06 Charles Birnstiel Elevated rail transit guideway with noise attenuators
US4093120A (en) 1977-01-24 1978-06-06 Park Rubber Company Railroad crossing structure
DE7711191U1 (de) 1977-04-07 1978-09-28 Straetner Geb. Buss, Anita, 4300 Essen Fahrbahnplatte fuer schienengleiche bahnuebergaenge
DE7719283U1 (de) 1977-06-20 1977-10-27 Gummiwerk Kraiburg Gmbh & Co, 8264 Waldkraiburg Platte fuer schienengleiche bahnuebergaenge
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE3827547C2 (de) * 1988-08-13 2000-09-21 Zueblin Ag Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
US4960184A (en) * 1989-11-09 1990-10-02 Bruce Woodward Sound absorbing structure
DE4243102A1 (en) * 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
US5730548A (en) * 1994-02-11 1998-03-24 Autostrade-Concessioni E Costruzioni Autostrade S.P.A. Deadening road pavement and method for its realization
DE4414566C2 (de) * 1994-04-27 1997-11-20 Freudenberg Carl Fa Luftschalldämpfer
DE4417402A1 (de) 1994-05-18 1995-11-23 Gruenzweig & Hartmann Montage Schallschutzeinrichtung zur Schalldämpfung und -dämmung an Gleiskörpern
NL194553C (nl) * 1994-06-06 2002-07-02 Veldhoen Raalte B V Inrichting voor de geluidsisolatie van een spoorbaan.
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau
IT1293307B1 (it) * 1997-07-09 1999-02-16 Dieselbox Sa Barriera antirumore a pannelli trasparenti,dotata di caratteristiche fonoisolanti e fonoassorbenti

Also Published As

Publication number Publication date
HUP9903612A3 (en) 2001-08-28
EP0901536A1 (de) 1999-03-17
DK0901536T3 (da) 2003-04-07
NO985600L (no) 1998-11-30
CA2255946A1 (en) 1997-12-04
WO1997045592A1 (de) 1997-12-04
NO985600D0 (no) 1998-11-30
NO316078B1 (no) 2003-12-08
CA2255946C (en) 2006-03-14
HUP9903612A2 (hu) 2000-02-28
CN1219989A (zh) 1999-06-16
ATE229595T1 (de) 2002-12-15
JP3822641B2 (ja) 2006-09-20
CN100424268C (zh) 2008-10-08
US6253872B1 (en) 2001-07-03
DE59708955D1 (de) 2003-01-23
TW345603B (en) 1998-11-21
ES2186891T3 (es) 2003-05-16
HU221872B1 (hu) 2003-02-28
AU738889B2 (en) 2001-09-27
AU2880197A (en) 1998-01-05
JP2000510921A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
EP0901536B1 (de) Schallschutzeinrichtung für gleise
EP0904461B1 (de) Schienengleiche eindeckung für gleise
DE2321676A1 (de) Schallschutzwand aus gummi-verbundwerkstoffen
EP2817457B1 (de) Lärmschutzvorrichtung
EP0214524B1 (de) Mauerwerk- oder Pflasterstein aus Beton oder dergleichen
DE4220547A1 (de) Laermschutzelement fuer laermschutzwaende
DE19620731A1 (de) Feste Fahrbahn für schienengebundene Fahrzeuge auf Brücken und Verfahren zu ihrer Herstellung
DE102007037339A1 (de) Gabionenkorb mit lärmdämmender, monolithischer Schicht aus Beton
DE3827547C2 (de) Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
DE3134473A1 (de) Schotterloser oberbau fuer schienenbahnen
DE202011052057U1 (de) Lärmschutzvorrichtung
DE4430769C2 (de) Eisenbahnoberbau mit einem auf einer durchgehenden Tragplatte aus Stahlbeton aufgelagerten Gleisrost
AT512523B1 (de) Fundamentlose Lärmschutzvorrichtung
DE19514458A1 (de) Schallabsorbierendes Wandelement
DE3544481A1 (de) Schallschutzwand und dafuer geeignetes wandelement
DE2937478A1 (de) Bauteilsatz und bauelement zur herstellung von bauwerken sowie damit gebildete mauer und verwendung zur mauerherstellung
AT500820B1 (de) Fahrschiene für einen schienentrog
DE3727947A1 (de) Schallabsorbierendes bauelement sowie verfahren zur herstellung desselben
AT403809B (de) Schallschutzeinrichtung für gleise
DE19540357C1 (de) Eisenbahnbrücke und Kulisse zur Schalldämpfung an dieser
DE19635788A1 (de) Schalldämpfungselement für Schienentrassen mit fester Fahrbahn
EP1136622B1 (de) Gleiseindeckung
AT512391B1 (de) Lärmschutzvorrichtung
DE19957223A1 (de) Plattenschwelle
EP0166719A2 (de) Profildichtung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE DK ES FI FR GB IT LI LU PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 981130

17Q First examination report despatched

Effective date: 20000830

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT CH DE DK ES FI FR GB IT LI LU PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 19981130

REF Corresponds to:

Ref document number: 229595

Country of ref document: AT

Date of ref document: 20021215

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 59708955

Country of ref document: DE

Date of ref document: 20030123

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20030329

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2186891

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030912

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG

Free format text: GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG.#KUFERZEILE 30-32#A-4810 GMUNDEN (AT) -TRANSFER TO- GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG.#KUFERZEILE 30-32#A-4810 GMUNDEN (AT)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20120529

Year of fee payment: 16

Ref country code: DK

Payment date: 20120522

Year of fee payment: 16

Ref country code: LU

Payment date: 20120530

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120529

Year of fee payment: 16

Ref country code: GB

Payment date: 20120425

Year of fee payment: 16

Ref country code: SE

Payment date: 20120518

Year of fee payment: 16

Ref country code: FI

Payment date: 20120523

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120516

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120730

Year of fee payment: 16

Ref country code: ES

Payment date: 20120504

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20120427

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120525

Year of fee payment: 16

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20131125

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 229595

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130531

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130524

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131125

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131203

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20130531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 59708955

Country of ref document: DE

Effective date: 20131203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140131

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20140225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523